Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Biogen (BIIB)

NASDAQ: BIIB · Biotechnology · Cambridge, MA

Our rating: Cautious

Cautious reaffirmed at $254.46, moderate conviction, November 4, 2026.

Breaks if: The Cautious call is wrong if Biogen reports two consecutive quarters of year-on-year revenue growth at or above 7%, demonstrating that a new-product ramp is genuinely offsetting franchise erosion at scale; or if both the October and November patent invalidations are reversed on appeal and confirmed within 12 months. A sustained move above $315 without that fundamental evidence would also compel a reassessment.

Key figures

Market value$36.9B
Revenue, last 12 months$10.3B
Net income, last 12 months$348M
Free cash flow, last 12 months$2.1B
Price to earnings106.2×
Free cash flow yield5.6%
Dividend yield0.0%
Operating marginn/a
Return on equity1.9%
Beta to the S&P 5000.49
Volatility, annualized31.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$2.8B10.6%$-0.14$600M
June 30, 2026$2.7B3.4%$0.66$408M
March 31, 2026$2.5B1.9%$2.15$594M
December 31, 2025$2.3B−7.1%$-0.35$468M
September 30, 2025$2.5B2.8%$3.17$1.2B
June 30, 2025$2.6B7.3%$4.33$134M
March 31, 2025$2.4B6.1%$1.64$222M
December 31, 2024$2.5B2.9%$1.83$722M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 42 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.